Skip Navigation
Search Menu
Find an Expert

 


Richard B. S. Roden, Ph.D.

Photo of Dr. Richard B. S. Roden, Ph.D.

Co-director, Cancer Prevention and Control Program, Sidney Kimmel Comprehensive Cancer Center

Professor of Pathology

Male

Research Interests: Human papillomavirus (HPV); ovarian cancer; HPV virology; HPV preventive vaccine; ovarian cancer pathogenesis; proteosome inhibitor; experimental therapeutics ...read more

Background

Dr. Richard Roden is a professor of pathology, gynecology and obstetrics, and oncology at the Johns Hopkins University School of Medicine. He also co-directs the Johns Hopkins Kimmel Cancer Center's Cancer Prevention and Control Program. His research focuses on the pathology of cervical and ovarian cancer.

Dr. Roden’s team is currently engaged in research to prevent cervical cancer through the development of a preventative vaccine that is active against all oncogenic types of human papillomavirus (HPV). The team is also focused on identifying novel tumor antigens of significance in the biology of ovarian cancer that are applicable as biomarkers for early detection or targets for immunotherapy. In addition, his team has studied proteasome inhibitors as an innovative approach for treating gynecologic cancer and built tissue banks to enable research and ovarian cancer genome sequencing.

He holds a B.Sc. in biochemistry from Bristol University and a Ph.D. in biochemistry from the University of Cambridge. Following a fellowship and a position as visiting associate at National Cancer Institute in Bethesda, Maryland, he joined the faculty of Johns Hopkins in 1998.

...read more

Titles

  • Co-director, Cancer Prevention and Control Program, Sidney Kimmel Comprehensive Cancer Center
  • Professor of Pathology
  • Professor of Gynecology and Obstetrics
  • Professor of Oncology

Education

Additional Training

National Institutes of Cancer, Bethesda, MD, 1997

Research & Publications

Research Summary

The oncogenic genotypes of human papillomavirus (HPV), typified by HPV16, are the primary etiologic agent of cervical cancer. Papillomavirus has only two capsid proteins, L1 and L2. Both capsid proteins represent promising targets for prophylactic intervention. Dr. Roden’s lab has a primary research goal of preventing cervical cancer through the development of a preventative vaccine that is active against all oncogenic types of HPV. 


Little is known about the pathogenesis of ovarian cancer and there is currently no screening test for its detection while still confined to the ovary. The Roden lab is working to identify novel tumor antigens of significance in the biology of ovarian cancer and applicable as biomarkers for early detection or targets for immunotherapy.

Clinical Trials

Learn more about clinical trials at the Johns Hopkins Kimmel Cancer Center.

Selected Publications

View all on Pubmed

  1. Kwak K, Yemelyanova A, Roden RB. "Prevention of cancer by prophylactic human papillomavirus vaccines." Curr Opin Immunol. 2010 Dec 23.
  2. Peng S, Monie A, Kang TH, Hung CF, Roden R, Wu TC. "Efficient delivery of DNA vaccines using human papillomavirus pseudovirions." Gene Ther. 2010 Dec;17(12):1453-1464.
  3. Jones S, Wang TL, Shih Ie M, Mao TL, Nakayama K, Roden R, Glas R, Slamon D, Diaz LA Jr, Vogelstein B, Kinzler KW, Velculescu VE, Papadopoulos N. "Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma." Science. 2010 Oct 8;330(6001):228-231.
  4. Karanam B, Peng S, Li T, Buck C, Day PM, Roden RB. "Papillomavirus infection requires gamma secretase." J Virol. 2010 Oct;84(20):10661-10670.
  5. Ma B, Roden R, Wu TC. "Current status of human papillomavirus vaccines." J Formos Med Assoc. 2010 Jul;109(7):481-483.

Academic Affiliations & Courses

Graduate Program Affiliation

Graduate Program in Pathobiology

Is this you? Edit Profile